Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BMRN Stock Forecast 2026-2027
$59.07
Current Price
$11.25B
Market Cap
Buy 18
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to BMRN Price Targets
+103.1%
To High Target of $120.00
+59.1%
To Median Target of $94.00
-6.9%
To Low Target of $55.00
BMRN Price Momentum
-3.4%
1 Week Change
-1.3%
1 Month Change
-16.3%
1 Year Change
-0.6%
Year-to-Date Change
-19.3%
From 52W High of $73.18
+16.4%
From 52W Low of $50.76
📊 TOP ANALYST CALLS
Did BMRN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioMarin is one of their latest high-conviction picks.
Latest BMRN Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, BMRN has a bullish consensus with a median price target of $94.00 (ranging from $55.00 to $120.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $59.07, the median forecast implies a 59.1% upside. This outlook is supported by 18 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jessica Fye at JP Morgan, projecting a 103.1% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 6.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BMRN Analyst Ratings
18
Buy
5
Hold
0
Sell
BMRN Price Target Range
Low
$55.00
Average
$94.00
High
$120.00
Current: $59.07
Latest BMRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BMRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | B of A Securities | Geoff Meacham | Buy | Maintains | $85.00 |
| Mar 4, 2026 | Barclays | Eliana Merle | Overweight | Maintains | $105.00 |
| Mar 2, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Neutral | Reiterates | $55.00 |
| Feb 26, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $104.00 |
| Feb 25, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $86.00 |
| Feb 25, 2026 | Bernstein | William Pickering | Outperform | Maintains | $94.00 |
| Feb 25, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Neutral | Maintains | $55.00 |
| Feb 24, 2026 | Oppenheimer | Leland Gershell | Outperform | Maintains | $95.00 |
| Feb 18, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $75.00 |
| Feb 6, 2026 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $84.00 |
| Jan 20, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Upgrade | $98.00 |
| Dec 23, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $100.00 |
| Dec 22, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Neutral | Maintains | $60.00 |
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $60.00 |
| Nov 6, 2025 | Stifel | Paul Matteis | Hold | Downgrade | $61.00 |
| Nov 3, 2025 | Bernstein | William Pickering | Outperform | Maintains | $88.00 |
| Oct 28, 2025 | Barclays | Gena Wang | Overweight | Maintains | $80.00 |
| Oct 28, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $80.00 |
| Oct 28, 2025 | Stifel | Paul Matteis | Buy | Maintains | $73.00 |
| Oct 28, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $70.00 |
Biomarin Pharmaceutical Inc. (BMRN) Competitors
The following stocks are similar to BioMarin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biomarin Pharmaceutical Inc. (BMRN) Financial Data
Biomarin Pharmaceutical Inc. has a market capitalization of $11.25B with a P/E ratio of 32.8x. The company generates $3.22B in trailing twelve-month revenue with a 10.8% profit margin.
Revenue growth is +17.0% quarter-over-quarter, while maintaining an operating margin of +22.5% and return on equity of +5.9%.
Valuation Metrics
Market Cap
$11.25B
Enterprise Value
$10.44B
P/E Ratio
32.8x
PEG Ratio
-0.2x
Price/Sales
3.5x
Growth & Margins
Revenue Growth (YoY)
+17.0%
Gross Margin
+68.5%
Operating Margin
+22.5%
Net Margin
+10.8%
EPS Growth
+17.0%
Financial Health
Cash/Price Ratio
+13.7%
Current Ratio
5.2x
Debt/Equity
10.6x
ROE
+5.9%
ROA
+5.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biomarin Pharmaceutical Inc. (BMRN) Business Model
About Biomarin Pharmaceutical Inc.
What They Do
Biotechnology company focused on rare genetic therapies.
Business Model
The company develops and markets therapies to treat serious and life-threatening rare genetic diseases. It generates revenue through the sale of its approved treatments, which include enzyme replacement therapies, gene therapies, and small molecule drugs.
Additional Information
BioMarin operates in over 70 countries and has a strong pipeline of clinical candidates aimed at various genetic disorders. Established in 1997 and based in San Rafael, California, it plays a significant role in the biotechnology sector for rare diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3,221
CEO
Mr. Alexander Hardy
Country
United States
IPO Year
1999
Website
www.biomarin.comBiomarin Pharmaceutical Inc. (BMRN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Do Options Traders Know Something About BMRN Stock We Don't?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Mar 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
BioMarin Pharmaceutical Inc. (BMRN) presented at the Barclays 28th Annual Global Healthcare Conference, sharing insights relevant to investors in the healthcare sector.
Why It Matters
BioMarin's presentation at a major healthcare conference signals potential insights into its pipeline and strategies, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
BioMarin announced positive results for VOXZOGO, showing durable improvements in skeletal growth in children with achondroplasia, supported by over 10,000 patient-years of data.
Why It Matters
Positive data for VOXZOGO boosts BioMarin's market position as the sole treatment for achondroplasia, indicating potential for increased sales and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
4 days ago
Quick Summary
BioMarin Pharmaceutical Inc. (BMRN) presented at the Leerink Global Healthcare Conference, discussing its developments and strategies in the healthcare sector.
Why It Matters
BioMarin's presentation at a major healthcare conference could signal new developments or strategies, impacting stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
BioMarin Pharmaceutical Inc. (BMRN) presented at the TD Cowen 46th Annual Health Care Conference, providing insights into its current developments and future plans.
Why It Matters
BioMarin's presentation at a major health care conference can signal new developments or insights that may influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
BioMarin Pharmaceutical's PALYNZIQ has received FDA approval for use in pediatric patients aged 12 and older with PKU, showing significant blood phenylalanine reduction in Phase 3 study.
Why It Matters
BioMarin's FDA approval for PALYNZIQ expansion boosts its market potential in PKU treatment, likely enhancing revenue and investor confidence in the company's growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
BioMarin Pharmaceutical Inc. (BMRN) held its Q4 2025 earnings call, discussing financial results and company performance. Further details can be found in the full transcript.
Why It Matters
The Q4 2025 earnings call for BioMarin provides insight into the company's financial health, growth prospects, and strategic direction, influencing stock performance and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About BMRN Stock
What is Biomarin Pharmaceutical Inc.'s (BMRN) stock forecast for 2026?
Based on our analysis of 44 Wall Street analysts, Biomarin Pharmaceutical Inc. (BMRN) has a median price target of $94.00. The highest price target is $120.00 and the lowest is $55.00.
Is BMRN stock a good investment in 2026?
According to current analyst ratings, BMRN has 18 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $59.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BMRN stock?
Wall Street analysts predict BMRN stock could reach $94.00 in the next 12 months. This represents a 59.1% increase from the current price of $59.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biomarin Pharmaceutical Inc.'s business model?
The company develops and markets therapies to treat serious and life-threatening rare genetic diseases. It generates revenue through the sale of its approved treatments, which include enzyme replacement therapies, gene therapies, and small molecule drugs.
What is the highest forecasted price for BMRN Biomarin Pharmaceutical Inc.?
The highest price target for BMRN is $120.00 from Jessica Fye at JP Morgan, which represents a 103.1% increase from the current price of $59.07.
What is the lowest forecasted price for BMRN Biomarin Pharmaceutical Inc.?
The lowest price target for BMRN is $55.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a -6.9% decrease from the current price of $59.07.
What is the overall BMRN consensus from analysts for Biomarin Pharmaceutical Inc.?
The overall analyst consensus for BMRN is bullish. Out of 44 Wall Street analysts, 18 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $94.00.
How accurate are BMRN stock price projections?
Stock price projections, including those for Biomarin Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 9:39 PM UTC